Head-to-head evidence
HM15211 vs HRS-4729
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Obesity
Shared mechanism: GLP-1/GIP/glucagon receptor (triple) · full Obesity pipeline
HM15211
Developed by Hanmi Pharmaceutical
NCT03374241 · Phase 1 · completed
The study was randomized, blinded and placebo-controlled, a solid safety-study design, but its only primary measure was a count of adverse events rather than a clinical or weight-related efficacy outcome, and no statistical test was applied to those counts.
HRS-4729
Developed by Jiangsu Hengrui Pharmaceuticals
NCT06762600 · Phase 1 · completed
Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
Next expected readout: March 2027 · NCT07690826 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: HM15211's landscape · HRS-4729's landscape